Companion Diagnostics Market By Application (Colorectal Cancer Diagnostics, Breast Cancer Market, Lung Cancer, Melanoma, Urology, Gastric Cancer), By Technology (Polymerase Chain Reaction (PCR) Market, Situ Hybridization (ISH) Market, Immunohistochemistry (IHC) Market), By End User (Pharmaceutical Companies, Reference Labs), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jul 28, 2016

Key Findings


The global companion diagnostics market has been expected to grow with a CAGR of 23.2% during the forecast period of 2016-2022.


According to the FDA,”the companion diagnostic device is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The test helps a health care professional determine whether a particular therapeutic product’s benefits to patients will outweigh any potential serious side effects or risks”. Growing elder population is also driving the global companion market. North America region is dominating the companion diagnostic market globally, and one of the reasons for its dominance is due to a large number of elder population present in the region. Also, due to the technological advancements in medical field the market of companion diagnostic is growing rapidly, which is the major driver for the growth of the market.

Diseases like HIV and cancer are boosting the companion diagnostic market, as they help in deciding the specific dosage of drugs for the patients. The awareness regarding drugs toxicities among the patients and physicians is aiding to drive the market growth. But, the increasing cost of the research and development of the drugs has become the major restraint for the growth of the global companion diagnostics market. High R&D investments for the development of low cost medicines and the discovery of biomarkers and treatments of neurodegenerative diseases are the key opportunities present in the companion diagnostic market. Lack of awareness among the patients and government policies and regulation are the major challenges in front of the market.


Market Segment Insight


The companion diagnostics market is segmented into application, technology, and end user; other than geographical segmentation. On the basis of application, the market is sub-segmented into colorectal cancer, breast cancer, lung cancer, melanoma, urology, and gastric cancer. On the basis of technology, the market is sub segmented into polymerase chain reactor (PCR), in sute hybridization, immunohistochemistry, and other technologies i.e. NGS, multiplex Assay, cellular immune testing, Mab. On the basis of end user, the market is sub segmented into pharmaceutical companies, reference labs, and others. There has been a rising adoption of companion diagnostics in pharmaceutical companies and reference labs due to the rising demand of targeted drugs in infectious diseases, neurology, and oncology.


Molecular diagnostics is expected to be the fastest growing, and is largest market for the companion diagnostics majorly due to the utilization of techniques such as next generation sequencing, In Situ Hybridization, and real time PCR. Other factors which are helping the growth of the molecular diagnosis segment is the rising technological advancements in molecular diagnostics, which has enhanced precision and accuracy; and, has also decreased the cost of testing for utilizing these procedures.


Regional Insight


On the basis of regional outlook, companion diagnostics market has been divided into the regions of North America; Europe; Asia Pacific; Middle East and Africa; and, Latin America. In 2015, North America dominated with the market having the largestshare of the global market,followed by Europe, Asia Pacific, and Rest of the world due to growing base of the elder population and technological advancements in the region, which is also majorly driving the companion diagnostics market. A well-developed infrastructure in healthcare market in the North American region is one of the major reasons for the dominance of this region in the global companion diagnostics market. Rise in the R&D expenditure is also another factor driving the market in this region. Asia Pacific is expected to be the fastest growing region during the forecast period owing to increasing number of cases of chronic disorders in the countries like India and China, having the largest population base in the world. Medical tourism is another driver fetching the attraction of the patients due to cheap medical facilities in this region as compared to other regions.


Competitive Insight


Some of the key players of the industries are-Abbott Laboratories, Inc.; BioMerieux; Dako (Agilent Technologies); Leica Microsystems; Life Technologies; Myriad Genetics, Inc.; Qiagen; Resonance Health Ltd.; Roche; Ventana Medical Systems; Agilent Technologies, Inc.; BioGenex Laboratories; Danaher Corporation; GE Healthcare; Thermo Fisher Scientific, Inc. and more.


Acquisitions, innovations, and mergers are the key strategies adopted by the market players so as to sustain in the market. Recently,on 18th April 2016, Abbott Laboratories acquired St. Jude Medical, Inc., which is a medical product manufacturing company. On 1st June 2015, Leica Microsystems has acquired OCT Company Bioptigen, Inc. to strengthen its position in ophthalmology market. Similarly, on 3rd February 2015,Life Technologies has acquired Thermo Fisher Scientific Inc., these both are the key market player of companion diagnostic market. With the acquisition of Life Technologies, Thermo Fisher has established a new reporting segment, called Life Sciences Solutions. Mark Stevenson, who served as chief operating officer of Life Technologies, has been named as the executive vice president and president of Life Sciences Solutions.

CHAP 1. METHODOLOGY & SCOPE 1
1.1. RESEARCH METHODOLOGY 1
1.2. RESEARCH SCOPE & ASSUMPTIONS 1
1.3. LIST OF DATA SOURCES 1


CHAP 2. EXECUTIVE SUMMARY 1
2.1. GLOBAL COMPANION DIAGNOSTIC MARKET SUMMARY & KEY BUYING CRITERIA 1
2.2. GLOBAL COMPANION DIAGNOSTIC MARKET OUTLOOK 1
2.3. MARKET SEGMENTATION ANALYSIS 1
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 1
2.5. GLOBAL COMPANION DIAGNOSTIC MARKET VALUE CHAIN ANALYSIS 1
2.6. VENDOR LANDSCAPE 1


CHAP 3. GLOBAL COMPANION DIAGNOSTIC MARKET 1
3.1. MARKET DRIVER ANALYSIS 1
3.2. MARKET RESTRAINT ANALYSIS 1
3.3. KEY OPPORTUNITIES 1
3.4. CHALLENGES 1


CHAP 4. INDUSTRY ANALYSIS 1
4.1. GLOBAL COMPANION DIAGNOSTIC MARKET– PORTER’S FIVE FORCE MODEL 1
4.2. GLOBAL COMPANION DIAGNOSTIC MARKET– PESTEL ANALYSIS 1
4.3. GLOBAL COMPANION DIAGNOSTIC MARKET- GAP ANALYSIS 1


CHAP 5. GLOBAL COMPANION DIAGNOSTIC MARKET BY APPLICATION 2012-2022 ($ MILLION) 1
5.1. GLOBAL COMPANION COLORECTAL CANCER DIAGNOSTICS MARKET 2012-2022 ($ MILLION) 1
5.2. GLOBAL COMPANION BREAST CANCER MARKET 2012-2022 ($ MILLION) 1
5.3. GLOBAL COMPANION LUNG CANCER MARKET 2012-2022 ($ MILLION) 1
5.4. GLOBAL COMPANION MELANOMA MARKET 2012-2022 ($ MILLION) 1
5.5. GLOBAL COMPANION UROLOGY MARKET 2012-2022 ($ MILLION) 1
5.6. GLOBAL COMPANION GASTRIC CANCER MARKET 2012-2022 ($ MILLION) 1


CHAP 6. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2012-2022 ($ MILLION) 1
6.1. GLOBAL COMPANION DIAGNOSTIC POLYMERASE CHAIN REACTION (PCR) MARKET 2012-2022 ($ MILLION) 1
6.2. GLOBAL COMPANION DIAGNOSTIC IN SITU HYBRIDIZATION (ISH) MARKET 2012-2022 ($ MILLION) 1
6.3. GLOBAL COMPANION DIAGNOSTIC IMMUNOHISTOCHEMISTRY (IHC) MARKET 2012-2022 ($ MILLION) 1
6.4. GLOBAL COMPANION DIAGNOSTIC OTHER TECHNOLOGIES (NGS, MULTIPLEX ASSAY, CELLULAR IMMUNE TESTING, MAB) MARKET 2012-2022 ($ MILLION) 1


CHAP 7. GLOBAL COMPANION DIAGNOSTIC MARKET BY END USER 2012-2022 ($ MILLION) 1
7.1. GLOBAL COMPANION DIAGNOSTICS PHARMACEUTICAL COMPANIES MARKET 2012-2022 ($ MILLION) 1
7.2. GLOBAL COMPANION DIAGNOSTICS REFERENCE LABS MARKET 2012-2022 ($ MILLION) 1
7.3. GLOBAL COMPANION DIAGNOSTICS OTHERS MARKET 2012-2022 ($ MILLION) 1


CHAP 8. GLOBAL COMPANION DIAGNOSTIC MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 1
8.1. NORTH AMERICA 1
8.1.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.1.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.1.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 1
8.1.3.1. U.S. 1
8.1.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.1.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.1.3.2. CANADA 1
8.1.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.1.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.2. EUROPE 1
8.2.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.2.2. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.2.3. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 1
8.2.3.1. GERMANY 1
8.2.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.2.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.2.3.2. UK 1
8.2.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.2.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.2.3.3. FRANCE 1
8.2.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.2.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.2.3.4. SPAIN 1
8.2.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.2.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.2.3.5. REST OF EUROPE 1
8.2.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 1
8.2.3.5.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 1
8.3. ASIA PACIFIC 1
8.3.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.3.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.3.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 1
8.3.3.1. CHINA 1
8.3.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.3.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.3.3.2. INDIA 1
8.3.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.3.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.3.3.3. JAPAN 1
8.3.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.3.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 1
8.3.3.4. OTHERS 1
8.3.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($MILLION) 1
8.3.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 1
8.4. MIDDLE EAST & AFRICA 1
8.4.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.4.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.5. LATIN AMERICA 1
8.5.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.5.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
8.5.2.1. BRAZIL 1
8.5.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
8.5.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1


CHAP 9. COMPETITIVE LANDSCAPE 1
9.1. ABBOTT LABORATORIES, INC. 1
9.1.1. COMPANY OVERVIEW 1
9.1.2. FINANCIAL PERFORMANCE 1
9.1.3. PRODUCT BENCHMARKING 1
9.1.4. STRATEGIC INITIATIVES 1
9.2. BIOMERIEUX 1
9.2.1. COMPANY OVERVIEW 1
9.2.2. FINANCIAL PERFORMANCE 1
9.2.3. PRODUCT BENCHMARKING 1
9.2.4. STRATEGIC INITIATIVES 1
9.3. DAKO (AGILENT TECHNOLOGIES) 1
9.3.1. COMPANY OVERVIEW 1
9.3.2. FINANCIAL PERFORMANCE 1
9.3.3. PRODUCT BENCHMARKING 1
9.3.4. STRATEGIC INITIATIVES 1
9.4. LEICA MICROSYSTEMS 1
9.4.1. COMPANY OVERVIEW 1
9.4.2. FINANCIAL PERFORMANCE 1
9.4.3. PRODUCT BENCHMARKING 1
9.4.4. STRATEGIC INITIATIVES 1
9.5. LIFE TECHNOLOGIES. 1
9.5.1. COMPANY OVERVIEW 1
9.5.2. FINANCIAL PERFORMANCE 1
9.5.3. PRODUCT BENCHMARKING 1
9.5.4. STRATEGIC INITIATIVES 1
9.6. MYRIAD GENETICS, INC. 1
9.6.1. COMPANY OVERVIEW 1
9.6.2. FINANCIAL PERFORMANCE 1
9.6.3. PRODUCT BENCHMARKING 1
9.6.4. STRATEGIC INITIATIVES 1
9.7. QIAGEN 1
9.7.1. COMPANY OVERVIEW 1
9.7.2. FINANCIAL PERFORMANCE 1
9.7.3. PRODUCT BENCHMARKING 1
9.7.4. STRATEGIC INITIATIVES 1
9.8. RESONANCE HEALTH LTD. 1
9.8.1. COMPANY OVERVIEW 1
9.8.2. FINANCIAL PERFORMANCE 1
9.8.3. PRODUCT BENCHMARKING 1
9.8.4. STRATEGIC INITIATIVES 1
9.9. ROCHE 1
9.9.1. COMPANY OVERVIEW 1
9.9.2. FINANCIAL PERFORMANCE 1
9.9.3. PRODUCT BENCHMARKING 1
9.9.4. STRATEGIC INITIATIVES 1
9.10. VENTANA MEDICAL SYSTEMS 1
9.10.1. COMPANY OVERVIEW 1
9.10.2. FINANCIAL PERFORMANCE 1
9.10.3. PRODUCT BENCHMARKING 1
9.10.4. STRATEGIC INITIATIVES 1
9.11. AGILENT TECHNOLOGIES, INC. 1
9.11.1. COMPANY OVERVIEW 1
9.11.2. FINANCIAL PERFORMANCE 1
9.11.3. PRODUCT BENCHMARKING 1
9.11.4. STRATEGIC INITIATIVES 1
9.12. BIOGENEX LABORATORIES 1
9.12.1. COMPANY OVERVIEW 1
9.12.2. FINANCIAL PERFORMANCE 1
9.12.3. PRODUCT BENCHMARKING 1
9.12.4. STRATEGIC INITIATIVES 1
9.13. DANAHER CORPORATION 1
9.13.1. COMPANY OVERVIEW 1
9.13.2. FINANCIAL PERFORMANCE 1
9.13.3. PRODUCT BENCHMARKING 1
9.13.4. STRATEGIC INITIATIVES 1
9.14. GE HEALTHCARE 1
9.14.1. COMPANY OVERVIEW 1
9.14.2. FINANCIAL PERFORMANCE 1
9.14.3. PRODUCT BENCHMARKING 1
9.14.4. STRATEGIC INITIATIVES 1
9.15. THERMO FISHER SCIENTIFIC, INC. 1
9.15.1. COMPANY OVERVIEW 1
9.15.2. FINANCIAL PERFORMANCE 1
9.15.3. PRODUCT BENCHMARKING 1
9.15.4. STRATEGIC INITIATIVES 1

TABLE 1 GLOBAL COMPANION DIAGNOSTIC MARKET BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 2 GLOBAL COMPANION COLORECTAL CANCER DIAGNOSTICS MARKET 2012-2022 ($ MILLION) 1
TABLE 3 GLOBAL COMPANION BREAST CANCER MARKET 2012-2022 ($ MILLION) 1
TABLE 4 GLOBAL COMPANION LUNG CANCER MARKET 2012-2022 ($ MILLION) 1
TABLE 5 GLOBAL COMPANION MELANOMA MARKET 2012-2022 ($ MILLION) 1
TABLE 6 GLOBAL COMPANION UROLOGY MARKET 2012-2022 ($ MILLION) 1
TABLE 7 GLOBAL COMPANION GASTRIC CANCER MARKET 2012-2022 ($ MILLION) 1
TABLE 8 GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2012-2022 ($ MILLION) 1
TABLE 9 GLOBAL COMPANION DIAGNOSTIC POLYMERASE CHAIN REACTION (PCR) MARKET 2012-2022 ($ MILLION) 1
TABLE 10 GLOBAL COMPANION DIAGNOSTIC IN SITU HYBRIDIZATION (ISH) MARKET 2012-2022 ($ MILLION) 1
TABLE 11 GLOBAL COMPANION DIAGNOSTIC IMMUNOHISTOCHEMISTRY (IHC) MARKET 2012-2022 ($ MILLION) 1
TABLE 12 GLOBAL COMPANION DIAGNOSTIC OTHER TECHNOLOGIES (NGS, MULTIPLEX ASSAY, CELLULAR IMMUNE TESTING, MAB) MARKET 2012-2022 ($ MILLION) 1
TABLE 13 GLOBAL COMPANION DIAGNOSTIC MARKET BY END USER 2012-2022 ($ MILLION) 1
TABLE 14 GLOBAL COMPANION DIAGNOSTICS PHARMACEUTICAL COMPANIES MARKET 2012-2022 ($ MILLION) 1
TABLE 15 GLOBAL COMPANION DIAGNOSTICS REFERENCE LABS MARKET 2012-2022 ($ MILLION) 1
TABLE 16 GLOBAL COMPANION DIAGNOSTICS OTHERS MARKET 2012-2022 ($ MILLION) 1
TABLE 17 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 18 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 1
TABLE 19 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 20 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 21 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 22 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 23 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 24 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 25 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 1
TABLE 26 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 27 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 28 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 29 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 30 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 31 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 32 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 33 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 34 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 35 RUSSIA MARKET ESTIMATES AND FORECAST2012-2022 ($ MILLION) 1
TABLE 36 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 37 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 38 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 1
TABLE 39 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 40 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 41 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 42 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 43 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 44 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 45 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 46 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022 ($ MILLION) 1
TABLE 47 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 48 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 49 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 50 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 51 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1
TABLE 52 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
TABLE 53 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 1

FIGURE 1 MARKET SHARE BY REGION 1
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 8 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 9 REST OF EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 10 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 11 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 12 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 13 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 14 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 15 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1
FIGURE 16 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 1

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)